Efficacy of rivastigmine on executive function in patients with parkinson's disease dementia

Frederick A. Schmitt, Martin Farlow, Xiangyi Meng, Sibel Tekin, Jason T. Olin

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background and objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective was to investigate the effects of rivastigmine capsules versus placebo on EF in PDD, focusing on secondary outcome measures from a large, international, randomized, double-blind, placebo-controlled, 24-week trial (EXPRESS, CENA713B2311). Methods: Secondary outcomes included Delis-Kaplan Executive Function System (D-KEFS) measures of EF. Data from three D-KEFS subtests (Card Sorting, Letter Fluency, Color-Word Interference), plus the Symbol Digit Modalities Test were analyzed in the observed case (OC) population. Changes from baseline in the rivastigmine versus placebo groups were evaluated using the van Elteren test blocking for country. Results: Of 541 patients in the EXPRESS study, 402, 71, 97, and 65 patients provided data for Letter Fluency, Card Sorting and Color-Word Interference subtests, and the Symbol Digit Modalities Test, respectively. On Letter Fluency, rivastigmine was associated with improvements in correct responses, set loss errors, and responses made (all P < 0.05), but not repetition errors. Higher Card Sorting recognition description score (P= 0.03), and more correct substitutions on the Symbol Digit Modalities Test (P= 0.02) were also recorded. Conclusion: Rivastigmine was associated with significant improvements over placebo on EF tests evaluating flexibility of thinking, problem solving and planning in patients with PDD. These findings support the hypothesis that rivastigmine may affect frontal subcortical circuits, which potentially contributes to observed clinical improvement associated with EF.

Original languageEnglish
Pages (from-to)330-336
Number of pages7
JournalCNS Neuroscience and Therapeutics
Volume16
Issue number6
DOIs
StatePublished - Dec 2010

Fingerprint

Rivastigmine
Executive Function
Parkinson Disease
Dementia
Placebos
Color
Capsules
Alzheimer Disease

Keywords

  • Executive function
  • Parkinson's disease dementia
  • Rivastigmine
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Physiology (medical)
  • Psychiatry and Mental health
  • Pharmacology

Cite this

Efficacy of rivastigmine on executive function in patients with parkinson's disease dementia. / Schmitt, Frederick A.; Farlow, Martin; Meng, Xiangyi; Tekin, Sibel; Olin, Jason T.

In: CNS Neuroscience and Therapeutics, Vol. 16, No. 6, 12.2010, p. 330-336.

Research output: Contribution to journalArticle

Schmitt, Frederick A. ; Farlow, Martin ; Meng, Xiangyi ; Tekin, Sibel ; Olin, Jason T. / Efficacy of rivastigmine on executive function in patients with parkinson's disease dementia. In: CNS Neuroscience and Therapeutics. 2010 ; Vol. 16, No. 6. pp. 330-336.
@article{f990aef0613c44db8faefc139f22b1ae,
title = "Efficacy of rivastigmine on executive function in patients with parkinson's disease dementia",
abstract = "Background and objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective was to investigate the effects of rivastigmine capsules versus placebo on EF in PDD, focusing on secondary outcome measures from a large, international, randomized, double-blind, placebo-controlled, 24-week trial (EXPRESS, CENA713B2311). Methods: Secondary outcomes included Delis-Kaplan Executive Function System (D-KEFS) measures of EF. Data from three D-KEFS subtests (Card Sorting, Letter Fluency, Color-Word Interference), plus the Symbol Digit Modalities Test were analyzed in the observed case (OC) population. Changes from baseline in the rivastigmine versus placebo groups were evaluated using the van Elteren test blocking for country. Results: Of 541 patients in the EXPRESS study, 402, 71, 97, and 65 patients provided data for Letter Fluency, Card Sorting and Color-Word Interference subtests, and the Symbol Digit Modalities Test, respectively. On Letter Fluency, rivastigmine was associated with improvements in correct responses, set loss errors, and responses made (all P < 0.05), but not repetition errors. Higher Card Sorting recognition description score (P= 0.03), and more correct substitutions on the Symbol Digit Modalities Test (P= 0.02) were also recorded. Conclusion: Rivastigmine was associated with significant improvements over placebo on EF tests evaluating flexibility of thinking, problem solving and planning in patients with PDD. These findings support the hypothesis that rivastigmine may affect frontal subcortical circuits, which potentially contributes to observed clinical improvement associated with EF.",
keywords = "Executive function, Parkinson's disease dementia, Rivastigmine, Treatment",
author = "Schmitt, {Frederick A.} and Martin Farlow and Xiangyi Meng and Sibel Tekin and Olin, {Jason T.}",
year = "2010",
month = "12",
doi = "10.1111/j.1755-5949.2010.00182.x",
language = "English",
volume = "16",
pages = "330--336",
journal = "CNS Neuroscience and Therapeutics",
issn = "1755-5930",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Efficacy of rivastigmine on executive function in patients with parkinson's disease dementia

AU - Schmitt, Frederick A.

AU - Farlow, Martin

AU - Meng, Xiangyi

AU - Tekin, Sibel

AU - Olin, Jason T.

PY - 2010/12

Y1 - 2010/12

N2 - Background and objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective was to investigate the effects of rivastigmine capsules versus placebo on EF in PDD, focusing on secondary outcome measures from a large, international, randomized, double-blind, placebo-controlled, 24-week trial (EXPRESS, CENA713B2311). Methods: Secondary outcomes included Delis-Kaplan Executive Function System (D-KEFS) measures of EF. Data from three D-KEFS subtests (Card Sorting, Letter Fluency, Color-Word Interference), plus the Symbol Digit Modalities Test were analyzed in the observed case (OC) population. Changes from baseline in the rivastigmine versus placebo groups were evaluated using the van Elteren test blocking for country. Results: Of 541 patients in the EXPRESS study, 402, 71, 97, and 65 patients provided data for Letter Fluency, Card Sorting and Color-Word Interference subtests, and the Symbol Digit Modalities Test, respectively. On Letter Fluency, rivastigmine was associated with improvements in correct responses, set loss errors, and responses made (all P < 0.05), but not repetition errors. Higher Card Sorting recognition description score (P= 0.03), and more correct substitutions on the Symbol Digit Modalities Test (P= 0.02) were also recorded. Conclusion: Rivastigmine was associated with significant improvements over placebo on EF tests evaluating flexibility of thinking, problem solving and planning in patients with PDD. These findings support the hypothesis that rivastigmine may affect frontal subcortical circuits, which potentially contributes to observed clinical improvement associated with EF.

AB - Background and objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective was to investigate the effects of rivastigmine capsules versus placebo on EF in PDD, focusing on secondary outcome measures from a large, international, randomized, double-blind, placebo-controlled, 24-week trial (EXPRESS, CENA713B2311). Methods: Secondary outcomes included Delis-Kaplan Executive Function System (D-KEFS) measures of EF. Data from three D-KEFS subtests (Card Sorting, Letter Fluency, Color-Word Interference), plus the Symbol Digit Modalities Test were analyzed in the observed case (OC) population. Changes from baseline in the rivastigmine versus placebo groups were evaluated using the van Elteren test blocking for country. Results: Of 541 patients in the EXPRESS study, 402, 71, 97, and 65 patients provided data for Letter Fluency, Card Sorting and Color-Word Interference subtests, and the Symbol Digit Modalities Test, respectively. On Letter Fluency, rivastigmine was associated with improvements in correct responses, set loss errors, and responses made (all P < 0.05), but not repetition errors. Higher Card Sorting recognition description score (P= 0.03), and more correct substitutions on the Symbol Digit Modalities Test (P= 0.02) were also recorded. Conclusion: Rivastigmine was associated with significant improvements over placebo on EF tests evaluating flexibility of thinking, problem solving and planning in patients with PDD. These findings support the hypothesis that rivastigmine may affect frontal subcortical circuits, which potentially contributes to observed clinical improvement associated with EF.

KW - Executive function

KW - Parkinson's disease dementia

KW - Rivastigmine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=78649271714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649271714&partnerID=8YFLogxK

U2 - 10.1111/j.1755-5949.2010.00182.x

DO - 10.1111/j.1755-5949.2010.00182.x

M3 - Article

C2 - 20950329

AN - SCOPUS:78649271714

VL - 16

SP - 330

EP - 336

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

SN - 1755-5930

IS - 6

ER -